JP2014515040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515040A5 JP2014515040A5 JP2014510929A JP2014510929A JP2014515040A5 JP 2014515040 A5 JP2014515040 A5 JP 2014515040A5 JP 2014510929 A JP2014510929 A JP 2014510929A JP 2014510929 A JP2014510929 A JP 2014510929A JP 2014515040 A5 JP2014515040 A5 JP 2014515040A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- independently
- drug
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C**C(N)=C(***NC)I Chemical compound C**C(N)=C(***NC)I 0.000 description 3
- PZILMLQXTGDJCM-UHFFFAOYSA-N C(C1)NCCN1c1nnc(N2CCNCC2)nn1 Chemical compound C(C1)NCCN1c1nnc(N2CCNCC2)nn1 PZILMLQXTGDJCM-UHFFFAOYSA-N 0.000 description 1
- XSWILQCWFQOKIE-UHFFFAOYSA-N C1CC(c2nnc(C3NCCCC3)nn2)NCC1 Chemical compound C1CC(c2nnc(C3NCCCC3)nn2)NCC1 XSWILQCWFQOKIE-UHFFFAOYSA-N 0.000 description 1
- ITWARJUHZJXKNM-UHFFFAOYSA-N CC(C1)C=C(C)C=C1NC(OC1C=CCCCCC1)=O Chemical compound CC(C1)C=C(C)C=C1NC(OC1C=CCCCCC1)=O ITWARJUHZJXKNM-UHFFFAOYSA-N 0.000 description 1
- XLZCIYOGIKMDSG-UHFFFAOYSA-N CC(C1C2CCCCCC1)=NN=C2c1ccccn1 Chemical compound CC(C1C2CCCCCC1)=NN=C2c1ccccn1 XLZCIYOGIKMDSG-UHFFFAOYSA-N 0.000 description 1
- NGMHTEDSSHAFGW-UHFFFAOYSA-N Cc1c[nH]c(-c2nnc(-c3nc(C)c[nH]3)nn2)n1 Chemical compound Cc1c[nH]c(-c2nnc(-c3nc(C)c[nH]3)nn2)n1 NGMHTEDSSHAFGW-UHFFFAOYSA-N 0.000 description 1
- ASUZTNLCAHONDF-UHFFFAOYSA-N Cc1nnc(-c2ccccn2)nn1 Chemical compound Cc1nnc(-c2ccccn2)nn1 ASUZTNLCAHONDF-UHFFFAOYSA-N 0.000 description 1
- PMMSDMUGUYODMC-UHFFFAOYSA-N NCc1nnc(CN)nn1 Chemical compound NCc1nnc(CN)nn1 PMMSDMUGUYODMC-UHFFFAOYSA-N 0.000 description 1
- FOJXFFILELMRKJ-UHFFFAOYSA-N c1cnc(-c2nnc(-c3ncc[nH]3)nn2)[nH]1 Chemical compound c1cnc(-c2nnc(-c3ncc[nH]3)nn2)[nH]1 FOJXFFILELMRKJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166241.7 | 2011-05-16 | ||
| EP11166241 | 2011-05-16 | ||
| EP11166942 | 2011-05-20 | ||
| EP11166942.0 | 2011-05-20 | ||
| US201161515458P | 2011-08-05 | 2011-08-05 | |
| US201161515432P | 2011-08-05 | 2011-08-05 | |
| EP11176736.4 | 2011-08-05 | ||
| EP11176741.4 | 2011-08-05 | ||
| US61/515,458 | 2011-08-05 | ||
| EP11176741 | 2011-08-05 | ||
| EP11176736 | 2011-08-05 | ||
| US61/515,432 | 2011-08-05 | ||
| EP11192572 | 2011-12-08 | ||
| EP11192572.3 | 2011-12-08 | ||
| EP11192577.2 | 2011-12-08 | ||
| EP11192577 | 2011-12-08 | ||
| PCT/IB2012/052446 WO2012156919A1 (en) | 2011-05-16 | 2012-05-16 | Bio-orthogonal drug activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016161617A Division JP2017014262A (ja) | 2011-05-16 | 2016-08-22 | 生体直交型薬物活性化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515040A JP2014515040A (ja) | 2014-06-26 |
| JP2014515040A5 true JP2014515040A5 (enExample) | 2016-03-03 |
| JP5993940B2 JP5993940B2 (ja) | 2016-09-21 |
Family
ID=47176369
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510929A Active JP5993940B2 (ja) | 2011-05-16 | 2012-05-16 | 生体直交型薬物活性化 |
| JP2014510930A Active JP6482273B2 (ja) | 2011-05-16 | 2012-05-16 | 生体直交型薬物活性化 |
| JP2014510928A Active JP6215194B2 (ja) | 2011-05-16 | 2012-05-16 | 生体直交型薬物活性化 |
| JP2016161617A Ceased JP2017014262A (ja) | 2011-05-16 | 2016-08-22 | 生体直交型薬物活性化 |
| JP2018000737A Active JP6608467B2 (ja) | 2011-05-16 | 2018-01-05 | 生体直交型薬物活性化 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510930A Active JP6482273B2 (ja) | 2011-05-16 | 2012-05-16 | 生体直交型薬物活性化 |
| JP2014510928A Active JP6215194B2 (ja) | 2011-05-16 | 2012-05-16 | 生体直交型薬物活性化 |
| JP2016161617A Ceased JP2017014262A (ja) | 2011-05-16 | 2016-08-22 | 生体直交型薬物活性化 |
| JP2018000737A Active JP6608467B2 (ja) | 2011-05-16 | 2018-01-05 | 生体直交型薬物活性化 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US9931408B2 (enExample) |
| EP (4) | EP3973993A1 (enExample) |
| JP (5) | JP5993940B2 (enExample) |
| CN (4) | CN103732257A (enExample) |
| AU (3) | AU2012257417B2 (enExample) |
| CA (3) | CA2836365C (enExample) |
| DK (1) | DK2709667T3 (enExample) |
| ES (1) | ES2920373T3 (enExample) |
| WO (3) | WO2012156918A1 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9931408B2 (en) * | 2011-05-16 | 2018-04-03 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| CN104769127A (zh) | 2012-08-14 | 2015-07-08 | 10X基因组学有限公司 | 微胶囊组合物及方法 |
| US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
| US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| WO2014065860A1 (en) * | 2012-10-24 | 2014-05-01 | The General Hospital Corporation | Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions |
| WO2014081299A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| WO2014081300A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| US20150297741A1 (en) * | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| EP2922574B1 (en) | 2012-11-22 | 2023-05-17 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
| US9580553B2 (en) | 2012-12-07 | 2017-02-28 | University Of Washington Through Its Center For Commercialization | Thermally-activated self-immolative materials |
| US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
| CN108753766A (zh) | 2013-02-08 | 2018-11-06 | 10X基因组学有限公司 | 多核苷酸条形码生成 |
| US10570151B2 (en) | 2013-03-15 | 2020-02-25 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| DK2968495T3 (da) | 2013-03-15 | 2019-10-14 | Daniel J Capon | Hybrid immunoglobulin indeholdende en ikke-peptid-bro |
| US20150087043A1 (en) * | 2013-04-11 | 2015-03-26 | Coferon, Inc | Monomers capable of multimerizing in an aqueous solution that employ bioorthogonal chemistries, and methods of using same |
| EP3010486B1 (en) | 2013-06-19 | 2023-11-22 | The Regents of The University of California | Chemical structures for localized delivery of therapeutic agents |
| EA038192B1 (ru) | 2013-08-26 | 2021-07-21 | Регенерон Фармасьютикалз, Инк. | Фармацевтические композиции, содержащие диастереомеры макролида, способы их синтезирования и терапевтическое применение |
| CA2925106C (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| EP4176896B1 (en) * | 2014-01-31 | 2025-10-08 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2942724C (en) | 2014-03-14 | 2022-12-13 | The Regents Of The University Of California | Tco conjugates and methods for delivery of therapeutic agents |
| EP4169944A1 (en) | 2014-03-14 | 2023-04-26 | Biomolecular Holdings LLC | Process for preparing hybrid immunoglobulin containing non-peptidyl linkage |
| JP6787789B2 (ja) * | 2014-04-04 | 2020-11-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 詰め替え可能な薬物送達デバイスおよびその使用方法 |
| CN118910216A (zh) | 2014-06-26 | 2024-11-08 | 10X基因组学有限公司 | 分析来自单个细胞或细胞群体的核酸的方法 |
| US12312640B2 (en) | 2014-06-26 | 2025-05-27 | 10X Genomics, Inc. | Analysis of nucleic acid sequences |
| KR20190143491A (ko) | 2014-06-30 | 2019-12-30 | 타베다 세라퓨틱스, 인코포레이티드 | 표적화된 콘주게이트 및 입자 및 그것의 제형 |
| WO2016025480A1 (en) * | 2014-08-11 | 2016-02-18 | The General Hospital Corporation | Cyclooctenes for bioorthogonol reactions |
| CN104356110B (zh) * | 2014-11-19 | 2018-01-23 | 西北大学 | 一种硫诱导3,6‑芳香杂环不对称取代‑1,2,4,5‑四嗪化合物及其合成方法 |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| BR112017020149A8 (pt) | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| US20160331852A1 (en) * | 2015-05-11 | 2016-11-17 | Memorial Sloan Kettering Cancer Center | Radioligands for pretargeted pet imaging and methods of their therapeutic use |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| US10828373B2 (en) | 2015-09-10 | 2020-11-10 | Tambo, Inc. | Bioorthogonal compositions |
| GB201516480D0 (en) | 2015-09-17 | 2015-11-04 | Univ Edinburgh | Tetrazine as a trigger to release caged cargo |
| ES2874930T3 (es) * | 2015-10-08 | 2021-11-05 | Harvard College | Dispositivos recargables de administración de fármacos y procedimientos de uso de los mismos |
| HK1259311A1 (zh) | 2015-10-28 | 2019-11-29 | Tva (Abc), Llc | Sstr靶向綴合物及其顆粒和製劑 |
| US10875840B2 (en) * | 2015-12-15 | 2020-12-29 | University Of Delaware | Methods for inducing bioorthogonal reactivity |
| MA43094B1 (fr) | 2016-01-25 | 2020-10-28 | Regeneron Pharma | Dérivés de maytansinoïde, leurs conjugués, et procédés d'utilisation |
| US11690825B2 (en) | 2016-03-09 | 2023-07-04 | Board Of Regents, The University Of Texas System | 20-HETE receptor (GPR75) antagonists and methods of use |
| WO2017175613A1 (ja) * | 2016-04-06 | 2017-10-12 | 住友化学株式会社 | 複素環化合物 |
| EP3474901B1 (en) * | 2016-06-27 | 2025-08-06 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| AU2018207402B2 (en) | 2017-01-11 | 2023-09-28 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| EP3385779A1 (en) * | 2017-04-05 | 2018-10-10 | Koninklijke Philips N.V. | Multi-view display device and method |
| EP4458896A3 (en) | 2017-04-07 | 2025-01-08 | Tambo, Inc. | Bioorthogonal compositions |
| US11560384B2 (en) | 2017-05-04 | 2023-01-24 | University Of Utah Research Foundation | Benzonorbornadiene derivatives and reactions thereof |
| CN107281204A (zh) * | 2017-05-04 | 2017-10-24 | 北京大学 | 一种非对称的1，2，4，5‑四嗪分子的应用 |
| WO2019014549A1 (en) | 2017-07-14 | 2019-01-17 | The Penn State Research Foundation | Compositions and methods for targeted delivery of therapeutic and/or diagnostic species |
| EA039417B1 (ru) | 2017-08-07 | 2022-01-25 | Родин Терапеутикс, Инк. | Бициклические ингибиторы гистондеацетилазы |
| US10837047B2 (en) * | 2017-10-04 | 2020-11-17 | 10X Genomics, Inc. | Compositions, methods, and systems for bead formation using improved polymers |
| US10590244B2 (en) | 2017-10-04 | 2020-03-17 | 10X Genomics, Inc. | Compositions, methods, and systems for bead formation using improved polymers |
| WO2019084323A1 (en) | 2017-10-25 | 2019-05-02 | Georgia State University Research Foundation, Inc. | CHEMICAL RELEASE SYSTEM DELIVERED BY ENRICHMENT |
| SG11201913654QA (en) | 2017-11-15 | 2020-01-30 | 10X Genomics Inc | Functionalized gel beads |
| US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
| WO2019195888A1 (en) * | 2018-04-11 | 2019-10-17 | The University Of Melbourne | Targeting compounds and methods for their production |
| AU2019262521B2 (en) * | 2018-05-04 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
| US20210299286A1 (en) | 2018-05-04 | 2021-09-30 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| KR20250107972A (ko) | 2018-05-04 | 2025-07-14 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| US11584749B2 (en) | 2018-05-31 | 2023-02-21 | Spark Biopharma, Inc. | Phosphor-tetrazine compound and use thereof |
| KR102011772B1 (ko) * | 2018-05-31 | 2019-08-19 | (주)스파크바이오파마 | 신규한 형광체-테트라진 화합물 및 이의 용도 |
| EP3853234B1 (en) | 2018-09-18 | 2025-04-23 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| SG11202103393XA (en) | 2018-10-10 | 2021-04-29 | Tambo Inc | Processes for preparing functionalized cyclooctenes |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| EP3893935A4 (en) * | 2018-12-12 | 2022-12-28 | The General Hospital Corporation | PRODRUGS WITH TRIDENTATE SELF-IMMOLATING LINKER |
| CN112010817A (zh) * | 2019-05-31 | 2020-12-01 | 四川大学华西医院 | 一种制备四嗪类化合物的方法及其应用 |
| IL289095A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Activating components to cleave labels from biomolecules in vivo |
| IL289094A (en) * | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| DK3983363T3 (da) * | 2019-06-17 | 2024-06-24 | Tagworks Pharmaceuticals B V | Forbindelser til hurtig og effektiv klikfrigivelse |
| CN113321702B (zh) * | 2020-02-28 | 2022-08-05 | 国家纳米科学中心 | 一种单甲基澳瑞他汀f甲酯前药及其制备方法和应用 |
| CN113321698B (zh) * | 2020-02-28 | 2022-08-23 | 国家纳米科学中心 | 一种单甲基澳瑞他汀e前药及其制备方法和应用 |
| CN113354657B (zh) * | 2020-03-05 | 2022-10-21 | 国家纳米科学中心 | 一种Mytoxin A前药及其制备方法和应用 |
| EP3909944A1 (en) * | 2020-05-14 | 2021-11-17 | Rigshospitalet | Nuclide labelled h-tetrazines and use thereof for pet and spect pretargeted imaging and radionuclide therapy |
| US20230256109A1 (en) * | 2020-08-07 | 2023-08-17 | Tambo, Inc. | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy |
| WO2022047054A2 (en) | 2020-08-27 | 2022-03-03 | The Texas A&M University System | Inhibitors of sars cov-2 infection and uses thereof |
| WO2022072949A2 (en) * | 2020-10-02 | 2022-04-07 | The General Hospital Corporation | Bioorthogonal linkers and reactions |
| WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
| WO2023028165A2 (en) * | 2021-08-25 | 2023-03-02 | R.P. Scherer Technologies, Llc | Tumor-associated calcium signal transducer 2 (tacstd2) antibody-maytansine conjugates and methods of use thereof |
| US20250009890A1 (en) * | 2021-11-05 | 2025-01-09 | Tambo, Inc. | Trans-cyclooctene-modified bispecific antibodies |
| EP4186529B1 (en) * | 2021-11-25 | 2025-07-09 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
| IL314951B2 (en) | 2022-02-15 | 2025-07-01 | Tagworks Pharmaceuticals B V | Masked il12 protein |
| CN114652857B (zh) * | 2022-03-31 | 2023-10-20 | 成都大学 | 一种用于修复内皮糖萼受损的靶向药物递送系统及其制备方法 |
| CN115974892B (zh) * | 2022-12-27 | 2023-09-08 | 四川大学华西医院 | 三氮唑四嗪类化合物及其制备方法、应用 |
| CN116370650B (zh) * | 2023-04-14 | 2024-03-22 | 四川大学华西医院 | 基于四嗪连接子的多肽药物偶联物及其制备方法、应用 |
| CN116675664B (zh) * | 2023-04-21 | 2025-06-24 | 苏州大学 | 一种生物正交断键反应体系及前药与应用 |
| WO2025043219A1 (en) * | 2023-08-24 | 2025-02-27 | The Regents Of The University Of California | Methods for uncaging tetrazines |
| US20250243238A1 (en) * | 2024-01-31 | 2025-07-31 | Oregon State University | Tetrazine amino acids and methods for their production and use |
| CN117700394B (zh) * | 2024-02-06 | 2024-05-28 | 南京大学 | 一类可与非张力烯基硼酸快速环加成反应的四嗪类化合物及其生物医药应用 |
| WO2025174248A1 (en) * | 2024-02-16 | 2025-08-21 | Tagworks Pharmaceuticals B.V. | Trans-cyclooctenes with "or gate" release |
| CN117752824A (zh) * | 2024-02-21 | 2024-03-26 | 中国医学科学院医学实验动物研究所 | 预靶向肿瘤免疫探针、生物正交制剂、试剂盒及应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826964A (en) | 1982-07-20 | 1989-05-02 | Sri International | Bridged oxygen analogs of daunorubcin and doxorubicin |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4486444A (en) | 1983-06-20 | 1984-12-04 | Merck & Co., Inc. | (Hydroxybenzoyl)thiophenesulfonamide and acyl derivatives thereof for the topical treatment of elevated intraocular pressure |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5198560A (en) | 1990-04-27 | 1993-03-30 | Bristol-Myers Squibb Company | Cytotoxic bicyclo[7.3.1]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| EP0904066A4 (en) | 1996-05-03 | 2002-04-24 | Roger S Cubicciotti | DRUG COMPOSITIONS AND METHOD FOR ADMINISTERING DRUGS USING SYNTHETIC RECEPTORS |
| EP0973540B1 (en) | 1997-02-25 | 2005-11-02 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US8236949B2 (en) * | 2007-07-17 | 2012-08-07 | University Of Delaware | Tetrazine-based bio-orthogonal coupling reagents and methods |
| WO2009109998A1 (en) | 2008-03-03 | 2009-09-11 | Lupin Limited | Novel protein tyrosine phosphatase - ib inhibitors |
| US8900549B2 (en) * | 2008-10-31 | 2014-12-02 | The General Hospital Corporation | Compositions and methods for delivering a substance to a biological target |
| GB0906379D0 (en) * | 2009-04-14 | 2009-05-20 | Kencryst Ltd | Reduced sodium salt |
| ES2769538T3 (es) | 2009-04-16 | 2020-06-26 | Tagworks Pharmaceuticals B V | Kit de predireccionamiento, método y agentes que se usan en éste |
| EP2419141A1 (en) * | 2009-04-16 | 2012-02-22 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| WO2012012612A2 (en) | 2010-07-23 | 2012-01-26 | University Of Delaware | Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes |
| JP6063384B2 (ja) * | 2010-10-14 | 2017-01-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | プレターゲットキット、プレターゲット方法及びその使用試薬 |
| WO2012085789A1 (en) * | 2010-12-21 | 2012-06-28 | Koninklijke Philips Electronics N.V. | Agents for clearing biomolecules from circulation |
| EP2522369A1 (en) * | 2011-05-09 | 2012-11-14 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| US9931408B2 (en) | 2011-05-16 | 2018-04-03 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| WO2014065860A1 (en) | 2012-10-24 | 2014-05-01 | The General Hospital Corporation | Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions |
| EP2922574B1 (en) | 2012-11-22 | 2023-05-17 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
| US20150297741A1 (en) | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| WO2016025480A1 (en) | 2014-08-11 | 2016-02-18 | The General Hospital Corporation | Cyclooctenes for bioorthogonol reactions |
| EP3474901B1 (en) * | 2016-06-27 | 2025-08-06 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| US20210299286A1 (en) * | 2018-05-04 | 2021-09-30 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
| AU2019262521B2 (en) * | 2018-05-04 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Compounds comprising a linker for increasing transcyclooctene stability |
| IL289094A (en) * | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for increasing the speed and yield of the "click release" reaction |
| DK3983363T3 (da) * | 2019-06-17 | 2024-06-24 | Tagworks Pharmaceuticals B V | Forbindelser til hurtig og effektiv klikfrigivelse |
| IL289095A (en) * | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Activating components to cleave labels from biomolecules in vivo |
-
2012
- 2012-05-16 US US14/117,655 patent/US9931408B2/en active Active
- 2012-05-16 CN CN201280035091.1A patent/CN103732257A/zh active Pending
- 2012-05-16 AU AU2012257417A patent/AU2012257417B2/en active Active
- 2012-05-16 CN CN201280035096.4A patent/CN103889459B/zh active Active
- 2012-05-16 WO PCT/IB2012/052445 patent/WO2012156918A1/en not_active Ceased
- 2012-05-16 CA CA2836365A patent/CA2836365C/en active Active
- 2012-05-16 CN CN201810251663.9A patent/CN108524510A/zh active Pending
- 2012-05-16 EP EP21208293.7A patent/EP3973993A1/en active Pending
- 2012-05-16 JP JP2014510929A patent/JP5993940B2/ja active Active
- 2012-05-16 WO PCT/IB2012/052447 patent/WO2012156920A1/en not_active Ceased
- 2012-05-16 AU AU2012257418A patent/AU2012257418B2/en active Active
- 2012-05-16 WO PCT/IB2012/052446 patent/WO2012156919A1/en not_active Ceased
- 2012-05-16 CA CA2836338A patent/CA2836338C/en active Active
- 2012-05-16 EP EP12725515.6A patent/EP2709667B1/en active Active
- 2012-05-16 EP EP12725516.4A patent/EP2709668A1/en not_active Withdrawn
- 2012-05-16 US US14/117,125 patent/US20160151505A1/en not_active Abandoned
- 2012-05-16 ES ES12725515T patent/ES2920373T3/es active Active
- 2012-05-16 JP JP2014510930A patent/JP6482273B2/ja active Active
- 2012-05-16 JP JP2014510928A patent/JP6215194B2/ja active Active
- 2012-05-16 AU AU2012257416A patent/AU2012257416B8/en active Active
- 2012-05-16 CA CA2836361A patent/CA2836361C/en active Active
- 2012-05-16 EP EP12725514.9A patent/EP2709666B1/en active Active
- 2012-05-16 DK DK12725515.6T patent/DK2709667T3/da active
- 2012-05-16 US US14/117,246 patent/US9421274B2/en active Active
- 2012-05-16 CN CN201280024028.8A patent/CN103732256A/zh active Pending
-
2015
- 2015-12-30 US US14/983,858 patent/US10376594B2/en active Active
-
2016
- 2016-08-22 JP JP2016161617A patent/JP2017014262A/ja not_active Ceased
- 2016-11-23 US US15/233,283 patent/US10004810B2/en active Active
-
2018
- 2018-01-05 JP JP2018000737A patent/JP6608467B2/ja active Active
-
2019
- 2019-07-15 US US16/512,038 patent/US10967069B2/en active Active
-
2021
- 2021-02-05 US US17/169,217 patent/US11857636B2/en active Active
-
2023
- 2023-10-30 US US18/497,645 patent/US20240091371A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5993940B2 (ja) | 生体直交型薬物活性化 | |
| JP2014515040A5 (enExample) | ||
| WO2014081301A1 (en) | Bio-orthogonal drug activation |